What does HER2 status mean for Breast Cancer treatment

Understanding HER2 Status in Breast Cancer Treatment

HER2 status is one of the most important factors your oncology team considers when planning your breast cancer treatment. Let me explain what it means and why it matters.

What is HER2?

HER2 (human epidermal growth factor receptor 2) is a protein found on the surface of cells that normally helps cells grow and divide. In some breast cancers, cancer cells have too many copies of the HER2 gene or too many HER2 receptors—this is called HER2-positive (HER2+) or HER2 overexpression.

Think of it like this: normal cells have a certain number of "growth switches" on their surface. HER2+ cancer cells have many more of these switches turned on, causing them to grow faster and more aggressively.

How is HER2 Status Tested?

According to NCCN Guidelines, HER2 testing should be done on all new breast cancer tumors using one of two methods:

Immunohistochemistry (IHC): This test measures HER2 receptors directly. Results are scored as:

• 0 or 1+ = HER2-negative (HER2-)
• 2+ = Equivocal (unclear—requires additional testing)
• 3+ = HER2-positive (HER2+)

In Situ Hybridization (ISH): This test counts the actual number of HER2 gene copies in cancer cells. It's typically used when IHC results are unclear (2+).

What HER2 Status Means for Your Treatment

Your HER2 status fundamentally shapes which treatments your doctor will recommend:

If You're HER2-Positive (HER2+)

According to NCCN Guidelines for Invasive Breast Cancer, HER2+ cancers are treated with HER2-targeted therapy, which includes:

• HER2 antibodies (like trastuzumab/Herceptin and pertuzumab/Perjeta) that block HER2 growth signals
• HER2 inhibitors (like neratinib) that stop growth signals from inside the cell
• HER2 antibody-drug conjugates (like trastuzumab deruxtecan/Enhertu) that deliver chemotherapy directly to HER2+ cells

These are often combined with chemotherapy and, if your cancer is also hormone receptor-positive (HR+), with endocrine therapy (hormone-blocking drugs).

If You're HER2-Negative (HER2-)

Treatment focuses on other factors:

• HR+ with HER2-: Endocrine therapy (hormone therapy) is the primary treatment, sometimes combined with CDK4/6 inhibitors
• HR- with HER2-: Chemotherapy is typically the first-line treatment

Important Recent Development: HER2-Low Breast Cancer

According to NCCN Guidelines, there's an emerging category called HER2-low (IHC 1+ or 2+ with negative ISH). Recent FDA approvals have opened new treatment options for this group, including newer targeted drugs that were previously only used for HER2+ cancers.

Why HER2 Status Matters

HER2-targeted therapies have dramatically improved outcomes for HER2+ breast cancer patients. These drugs are specifically designed to attack the HER2 protein, making them highly effective while potentially causing fewer side effects than traditional chemotherapy alone.

Questions to Ask Your Oncologist

Since HER2 status is so important, here are key questions to discuss with your care team:

1. What is my exact HER2 status? (Ask for the specific IHC score or ISH result)
2. Based on my HER2 status and other tumor characteristics, what treatment options are available to me?
3. Will I receive HER2-targeted therapy, and if so, for how long?
4. What side effects should I expect from HER2-targeted therapy? (Heart function monitoring is important with some HER2 drugs)
5. Are there any clinical trials available for my specific HER2 status?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.